Neogen Corp 10-Q for FY2020 Q3
Neogen Corp (NEOG)
About this 10-Q
Neogen Corp filed this 10-Q on April 3, 2020, covering the quarter ended February 29, 2020 (FY2020 Q3).
Headline figures
Quarter ended February 29, 2020, as reported in this filing, compared with the same period a year earlier where the filing states it.
- Revenue
- $99.87M
- up 2.2% from $97.7M a year earlier
- Net income
- $12.2M
- down 6.7% from net income of $13.07M a year earlier
- Diluted EPS
- $0.23
- down 8.0% from $0.25 a year earlier
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
| |
| |
| (State or other jurisdiction of incorporation or organization) |
(IRS Employer Identification Number) |
| Title of each Class |
Trading Symbol(s) |
Name of each exchange on which registered | ||
| |
|
|
| |
☒ |
Accelerated filer |
☐ | |||
| Non-accelerated filer |
☐ |
Smaller Reporting Company |
| |||
| Emerging growth company |
|
| Page No. |
||||||
| Item 1. |
2 |
|||||
| 2 |
||||||
| 3 |
||||||
| 4 |
||||||
| 5 |
||||||
| 6 |
||||||
| 7 |
||||||
| Item 2. |
19 |
|||||
| Item 3. |
27 |
|||||
| Item 4. |
27 |
|||||
| Item 1. |
28 |
|||||
| Item 1A. |
28 |
|||||
| Item 6. |
28 |
|||||
| 29 |
||||||
| February 29, 2020 |
2019 |
|||||||
| Unaudited |
Un udited a |
|||||||
| Assets |
||||||||
| Current Assets |
||||||||
| Cash and cash equivalents |
$ | |
$ | |
||||
| Marketable securities |
|
|
||||||
| Accounts receivable, less allowance of $ |
|
|
||||||
| Inventories |
|
|
||||||
| Prepaid expenses and other current assets |
|
|
||||||
| Total Current Assets |
|
|
||||||
| Net Property and Equipment |
|
|
||||||
| Other Assets |
||||||||
| Goodwill |
|
|
||||||
| Other non-amortizable intangible assets |
|
|
||||||
| Amortizable intangible and other assets, net of accumulated amortization of $ |
|
|
||||||
| Total Assets |
$ | |
$ | |
||||
| Liabilities and Stockholders’ Equity |
||||||||
| Current Liabilities |
||||||||
| Accounts payable |
$ | |
$ | |
||||
| Accrued compensation |
|
|
||||||
| Income taxes |
|
|
||||||
| Other accruals |
|
|
||||||
| Total Current Liabilities |
|
|
||||||
| Deferred Income Taxes |
|
|
||||||
| Other Non-Current Liabilities |
|
|
||||||
| Total Liabilities |
|
|
||||||
| Commitments and Contingencies (note 8) |
||||||||
| Equity |
||||||||
| Preferred stock, $ |
|
— |
||||||
| Common stock, $ |
|
|
||||||
| Additional paid-in capital |
|
|
||||||
| Accumulated other comprehensive loss |
( |
) | ( |
) | ||||
| Retained earnings |
|
|
||||||
| Total Stockholders’ Equity |
|
|
||||||
| Total Liabilities and Stockholders’ Equity |
$ | |
$ | |
||||
| Three Months Ended |
Nine Months Ended |
|||||||||||||||
| February 29/28, |
February 29/28, |
|||||||||||||||
| 2020 |
2019 |
2020 |
2019 |
|||||||||||||
| Revenues |
||||||||||||||||
| Product revenues |
$ | |
$ | |
$ | |
$ | |
||||||||
| Service revenues |
|
|
|
|
||||||||||||
| Total Revenues |
|
|
|
|
||||||||||||
| Cost of Revenues |
||||||||||||||||
| Cost of product revenues |
|
|
|
|
||||||||||||
| Cost of service revenues |
|
|
|
|
||||||||||||
| Total Cost of Revenues |
|
|
|
|
||||||||||||
| Gross Margin |
|
|
|
|
||||||||||||
| Operating Expenses |
||||||||||||||||
| Sales and marketing |
|
|
|
|
||||||||||||
| General and administrative |
|
|
|
|
||||||||||||
| Research and development |
|
|
|
|
||||||||||||
| Total Operating Expenses |
|
|
|
|
||||||||||||
| Operating Income |
|
|
|
|
||||||||||||
| Other Income (Expense) |
||||||||||||||||
| Interest income |
|
|
|
|
||||||||||||
| Other income (expense) |
( |
) | |
( |
) | |
||||||||||
| Total Other Income |
|
|
|
|
||||||||||||
| Income Before Taxes |
|
|
|
|
||||||||||||
| Provision for Income Taxes |
|
|
|
|
||||||||||||
| Net Income |
$ | |
$ | |
$ | |
$ | |
||||||||
| Net Income Per Share |
||||||||||||||||
| Basic |
$ |
|
$ | |
$ |
|
$ | |
||||||||
| Diluted |
$ |
|
$ | |
$ |
|
$ | |
||||||||
| Three Months Ended |
Nine Months Ended |
|||||||||||||||
| February 29/28, |
February 29/28, |
|||||||||||||||
| 2020 |
2019 |
2020 |
2019 |
|||||||||||||
| Net income |
$ | |
$ | |
$ | |
$ | |
||||||||
| Other comprehensive income (loss), net of tax: |
||||||||||||||||
| currency translation adjustments |
( |
) | |
( |
) | |
||||||||||
| Other comprehensive income, net of tax: |
||||||||||||||||
| unrealized gain on marketable securities |
|
— |
|
— |
||||||||||||
| Total comprehensive income |
$ | |
$ | |
$ | |
$ | |
||||||||
| Accumulated |
||||||||||||||||||||||||
| Additional |
Other |
|||||||||||||||||||||||
| Common Stock |
Paid-in |
Comprehensive |
Retained |
|||||||||||||||||||||
| Shares |
Amount |
Capital |
Income (Loss) |
Earnings |
Total |
|||||||||||||||||||
| Balance at May 31, 2019 |
|
$ |
|
$ |
|
$ |
( |
) |
$ |
|
$ |
|
||||||||||||
| Issuance of shares under share-based compensation plan |
|
|
|
— |
— |
|
||||||||||||||||||
| Issuance of shares under employee stock purchase plan |
|
|
|
— |
— |
|
||||||||||||||||||
| Net income for the three months ended August 31, 2019 |
— |
— |
— |
— |
|
|
||||||||||||||||||
| Other comprehensive loss for the three months ended August 31 , 2019 |
— |
— |
— |
( |
) |
— |
( |
) | ||||||||||||||||
| Balance at August 31, 2019 |
|
$ |
|
$ |
|
$ |
( |
) |
$ |
|
$ |
|
||||||||||||
| Issuance of shares under share-based compensation plan |
|
|
|
— |
— |
|
||||||||||||||||||
| Net income for the three months ended November 30, 2019 |
— |
— |
— |
— |
|
|
||||||||||||||||||
| Other comprehensive income for the three months ended November 30, 2019 |
— |
— |
— |
|
— |
|
||||||||||||||||||
| Balance at November 30, 2019 |
|
$ |
|
$ |
|
$ |
( |
) |
$ |
|
$ |
|
||||||||||||
| Issuance of shares under share-based compensation plan |
|
|
|
— |
— |
|
||||||||||||||||||
| Issuance of shares under employee stock purchase plan |
|
|
|
— |
— |
|
||||||||||||||||||
| Net income for the three months ended February 29, 2020 |
— |
— |
— |
— |
|
|
||||||||||||||||||
| Other comprehensive loss for the three months ended February 29 , 2020 |
— |
— |
— |
( |
) |
— |
( |
) | ||||||||||||||||
| Balance at February 29, 2020 |
|
$ |
|
$ |
|
$ |
( |
) |
$ |
|
$ |
|
||||||||||||
| Accumulated |
||||||||||||||||||||||||
| Additional |
Other |
|||||||||||||||||||||||
| Common Stock |
Paid-in |
Comprehensive |
Retained |
|||||||||||||||||||||
| Shares |
Amount |
Capital |
Income (Loss) |
Earnings |
Total |
|||||||||||||||||||
| Balance at May 31, 2018 |
|
$ |
|
$ |
|
$ |
( |
) |
$ |
|
$ |
|
||||||||||||
| Issuance of shares under share-based compensation plan |
|
|
|
— |
— |
|
||||||||||||||||||
| Issuance of shares under employee stock purchase plan |
|
|
|
— |
— |
|
||||||||||||||||||
| Net income for the three months ended August 31, 2018 |
— |
— |
— |
— |
|
|
||||||||||||||||||
| Other comprehensive loss for the three months ended August 31, 2018 |
— |
— |
— |
( |
) | — |
( |
) | ||||||||||||||||
| Balance at August 31, 2018 |
|
$ |
|
$ |
|
$ |
( |
) |
$ |
|
$ |
|
||||||||||||
| Issuance of shares under share-based compensation plan |
|
|
|
— |
— |
|
||||||||||||||||||
| Net income for the three months ended November 30, 2018 |
— |
— |
— |
— |
|
|
||||||||||||||||||
| Other comprehensive income for the three months ended November 30, 2018 |
— |
— |
— |
|
— |
|
||||||||||||||||||
| Balance at November 30, 2018 |
|
$ |
|
$ |
|
$ |
( |
) |
$ |
|
$ |
|
||||||||||||
| Issuance of shares under share-based compensation plan |
|
|
|
— |
— |
|
||||||||||||||||||
| Issuance of shares under employee stock purchase plan |
|
|
|
— |
— |
|
||||||||||||||||||
| Shares repurchased |
( |
) | ( |
) | ( |
) | — |
— |
( |
) | ||||||||||||||
| Net income for the three months ended February 28, 2019 |
— |
— |
— |
— |
|
|
||||||||||||||||||
| Other comprehensive loss for the three months ended February 28, 2019 |
— |
— |
— |
|
— |
|
||||||||||||||||||
| Balance at February 28, 2019 |
|
$ |
|
$ |
|
$ |
( |
) |
$ |
|
$ |
|
||||||||||||
| Nine Months Ended February 29/28, |
||||||||
| 2020 |
2019 |
|||||||
| Cash Flows From Operating Activities |
||||||||
| Net Income |
$ | |
$ | |
||||
| Adjustments to reconcile net income to net cash from operating activities: |
||||||||
| Depreciation and amortization |
|
|
||||||
| Share-based compensation |
|
|
||||||
| Change in operating assets and liabilities, net of business acquisitions: |
||||||||
| Accounts receivable |
|
( |
) | |||||
| Inventories |
( |
) | ( |
) | ||||
| Prepaid expenses and other current assets |
( |
) | ( |
) | ||||
| Accounts payable, accruals and other changes |
|
( |
) | |||||
| Net Cash From Operating Activities |
|
|
||||||
| Cash Flows For Investing Activities |
||||||||
| Purchases of property, equipment and other assets |
( |
) | ( |
) | ||||
| Proceeds from the sale of marketable securities |
|
|
||||||
| Purchases of marketable securities |
( |
) | ( |
) | ||||
| Business acquisitions, net of cash acquired |
( |
) | ( |
) | ||||
| Net Cash For Investing Activities |
( |
) | ( |
) | ||||
| Cash Flows From Financing Activities |
||||||||
| Exercise of stock options and issuance of employee stock purchase plan shares |
|
|
||||||
| Repurchase of common stock |
— |
( |
) | |||||
| Net Cash From Financing Activities |
|
|
||||||
| Effect of Exchange Rates on Cash |
( |
) | |
|||||
| Net Increase In Cash and Cash Equivalents |
|
|
||||||
| Cash and Cash Equivalents, Beginning of Period |
|
|
||||||
| Cash and Cash Equivalents, End of Period |
$ | |
$ | |
||||
| • | We elected the package of practical expedients available for transition that allow us to not reassess whether expired or existing contracts contain leases under the new definition of a lease, lease classification for expired or existing leases and whether previously capitalized initial direct costs would qualify for capitalization under ASC 842. |
| • | We did not elect to use hindsight when considering judgments and estimates such as assessments of lessee options to extend or terminate a lease or purchase the underlying asset. |
| • | For all asset classes, we elected to not recognize a right-of-use asset and lease liability for short-term leases. |
| • | For all asset classes, we elected to not separate non-lease components from lease components to which they relate and have accounted for the combined lease and non-lease components as a single lease component. |
| • | The determination of the discount rate used in a lease is our incremental borrowing rate that is based on what we would normally pay to borrow on a collateralized basis over a similar term an amount equal to the lease payments. |
| February 29, 2020 |
||||
| (in thousands) |
||||
| Right of use - assets |
$ | |
||
| Lease liabilities - current |
|
|||
| Lease liabilities - non-current |
|
|||
| February 29, 2020 |
||||
| Weighted average remaining lease term |
|
|||
| Weighted average discount rate |
|
|||
| Three Months Ended February 29, 2020 |
Nine Months Ended February 29, 2020 |
|||||||
| (in thousands) |
(in thousands) |
|||||||
| Operating leases |
$ | |
$ | |
||||
| Short term leases |
|
|
||||||
| Total lease expense |
$ | |
$ | |
||||
| Amount |
||||
| (in thousands) |
||||
| Years ending May 31, |
||||
| 2020 (1) |
$ |
|
||
| 2021 |
|
|||
| 2022 |
|
|||
| 2023 |
|
|||
| 2024 |
|
|||
| 2025 and thereafter |
|
|||
| Total lease payments |
|
|||
| Less: imputed interest |
|
|||
| Total lease liabilities |
$ | |
||
| (1) | Excluding the nine months ended February 29, 2020. |
| Future Minimum Lease Payments |
||||
| (in thousands) |
||||
| Years ending May 31, |
||||
| 2020 |
$ |
|
||
| 2021 |
|
|||
| 2022 |
|
|||
| 2023 |
|
|||
| Thereafter |
|
|||
$ |
|
|||
| • | Identification of the contract with a customer; |
| • | Identification of the performance obligations in the contract; |
| • | Determination of the transaction price; |
| • | Allocation of the transaction price to the performance obligations in the contract; and |
| • | Recognition of revenue when, or as, the Company satisfies the performance obligations. |
| • | Diagnostic test kits, dehydrated culture media and related products used by food producers and processors to detect harmful natural toxins, foodborne bacteria, allergens and levels of general sanitation; |
| • | Consumable products marketed to veterinarians and animal health product distributors; and |
| • | Rodenticides, disinfectants and insecticides to assist in the control of rodents, insects and disease in and around agricultural, food production and other facilities. |
| • | Genomic identification and related interpretive bioinformatic services; and |
| • | Other commercial laboratory services. |
| Three Months ended February 2 9 /28 , |
Nine Months ended February 2 9 /28 , |
|||||||||||||||
| 2020 |
2019 |
2020 |
2019 |
|||||||||||||
| (in thousands) |
||||||||||||||||
| Food Safety |
||||||||||||||||
| Natural Toxins, Allergens & Drug Residues |
$ | |
$ | |
$ | |
$ | |
||||||||
| Bacterial & General Sanitation |
|
|
|
|
||||||||||||
| Culture Media & Other |
|
|
|
|
||||||||||||
| Rodenticides, Insecticides & Disinfectants |
|
|
|
|
||||||||||||
| Genomics Services |
|
|
|
|
||||||||||||
| $ | |
$ | |
$ | |
$ | |
|||||||||
| Animal Safety |
||||||||||||||||
| Life Sciences |
$ | |
$ | |
$ | |
$ | |
||||||||
| Veterinary Instruments & Disposables |
|
|
|
|
||||||||||||
| Animal Care & Other |
|
|
|
|
||||||||||||
| Rodenticides, Insecticides & Disinfectants |
|
|
|
|
||||||||||||
| Genomics Services |
|
|
|
|
||||||||||||
| $ | |
$ | |
$ | |
$ | |
|||||||||
| Total Revenues |
$ | 99,869 |
$ | |
$ | 309,096 |
$ | |
||||||||
| February 29, |
May 31, |
|||||||
| 2020 |
2019 |
|||||||
| (in thousands) |
||||||||
| Raw materials |
$ | |
$ | |
||||
| Work-in-process |
|
|
||||||
| Finished and purchased goods |
|
|
||||||
| $ | |
$ | |
|||||
| Three Months Ended |
Nine Months Ended |
|||||||||||||||
| February 29/28, |
February 29/28, |
|||||||||||||||
| 2020 |
2019 |
2020 |
2019 |
|||||||||||||
| (in thousands, except per share amounts) |
||||||||||||||||
| Numerator for basic and diluted net income per share: |
||||||||||||||||
| Net income attributable to Neogen |
$ | |
$ | |
$ |
|
$ | |
||||||||
| Denominator for basic net income per share: |
||||||||||||||||
| Weighted average shares |
|
|
|
|
||||||||||||
| Effect of dilutive stock options |
|
|
|
|
||||||||||||
| Denominator for diluted net income per share |
|
|
|
|
||||||||||||
| Net income attributable to Neogen per share: |
||||||||||||||||
| Basic |
$ | |
$ | |
$ | |
$ | |
||||||||
| Diluted |
$ | |
$ | |
$ | |
$ | |
||||||||
| |
Food Safety |
Animal Safety |
Corporate and Eliminations (1) |
Total |
||||||||||||
| (in thousands) |
||||||||||||||||
| As of and for the three months ended February 29, 2020 |
||||||||||||||||
| Product revenues to external customers |
$ | |
$ | |
$ | — |
$ | |
||||||||
| Service revenues to external customers |
|
|
— |
|
||||||||||||
| Total revenues to external customers |
|
|
— |
|
||||||||||||
| Operating income (loss) |
|
|
( |
) | |
|||||||||||
| Total assets |
|
|
|
|
||||||||||||
| As of and for the three months ended February 28, 2019 |
||||||||||||||||
| Product revenues to external customers |
$ | |
$ | |
$ | — |
$ | |
||||||||
| Service revenues to external customers |
|
|
— |
|
||||||||||||
| Total revenues to external customers |
|
|
— |
|
||||||||||||
| Operating income (loss) |
|
|
( |
) | |
|||||||||||
| Total assets |
|
|
|
|
||||||||||||
| (1) | Includes corporate assets, consisting principally of cash and cash equivalents, marketable securities , current and deferred tax accounts and overhead expenses not allocated to specific business segments. Also includes the elimination of intersegment transactions. |
| |
Food Safety |
Animal Safety |
Corporate and Eliminations (1) |
Total |
||||||||||||
| (in thousands) |
||||||||||||||||
| As of and for the nine months ended February 29, 2020 |
||||||||||||||||
| Product revenues to external customers |
$ | |
$ | |
$ | — |
$ | |
||||||||
| Service revenues to external customers |
|
|
— |
|
||||||||||||
| Total revenues to external customers |
|
|
— |
|
||||||||||||
| Operating income (loss) |
|
|
( |
) | |
|||||||||||
| As of and for the nine months ended February 28, 2019 |
||||||||||||||||
| Product revenues to external customers |
$ | |
$ | |
$ | — |
$ | |
||||||||
| Service revenues to external customers |
|
|
— |
|
||||||||||||
| Total revenues to external customers |
|
|
— |
|
||||||||||||
| Operating income (loss) |
|
|
( |
) | |
|||||||||||
| (1) | Includes elimination of intersegment transactions. |
| Three months ended |
Nine months ended |
|||||||||||||||
| February 29/28, |
February 29/28, |
|||||||||||||||
| 2020 |
2019 |
2020 |
2019 |
|||||||||||||
| (in thousands) |
(in thousands) |
|||||||||||||||
| Revenues by Geographic Location |
||||||||||||||||
| Domestic |
$ | |
$ | |
$ | |
$ | |
||||||||
| International |
|
|
|
|
||||||||||||
| Total revenue |
|
|
|
|
||||||||||||
| Weighted- |
||||||||
| Average |
||||||||
| (Options in thousands) |
Shares |
Exercise Price |
||||||
| Options outstanding June 1, 2019 |
|
$ | |
|||||
| Granted |
|
|
||||||
| Exercised |
( |
) | |
|||||
| Forfeited |
( |
) | |
|||||
| Options outstanding February 29, 2020 |
|
$ | |
|||||
| FY 2020 |
||||
| Risk-free interest rate |
|
|||
| Expected dividend yield |
|
|||
| Expected stock price volatility |
|
|||
| Expected option life |
|
|||
Item 2. |
Management’s Discussion and Analysis of Financial Condition and Results of Operations |
| • | Consolidated revenues were $99.9 million in the third quarter of fiscal 2020, an increase of 2% compared to $97.7 million in the third quarter of fiscal 2019. Organic sales growth in the third quarter of fiscal 2020 was 1%. For the year to date period, consolidated revenues were $309.1 million, an increase of 2% compared to $304.4 million in the same period in the prior fiscal year. Organic sales rose 1% for the nine month period. |
| • | Food Safety segment sales were $50.5 million in the third quarter of the current fiscal year, a decline of 1% compared to $51.1 million in the same period of the prior year. Organic sales declined 3% during the quarter; contributions from four acquisitions executed during the quarter totaled $990,000. For the year to date, Food Safety segment sales were $158.4 million, an increase of 1% compared to $157.0 million in the same period of the prior fiscal year; excluding acquisitions, sales were flat. |
| • | Animal Safety segment sales were $49.4 million in the third quarter of fiscal 2020, an increase of 6% compared to $46.6 million in the third quarter of fiscal 2019. Organic sales in this segment also rose 6% in the third quarter, with only a minor contribution from the January 1, 2019 acquisition of Delta Genomics. For the year to date, Animal Safety segment sales were $150.7 million, an increase of 2% compared to $147.4 million in the same period a year ago. Year to date organic sales also increased 2%. |
| • | International sales in the third quarter of fiscal 2020 were 40% of total sales compared to 41% of total sales in the third quarter of fiscal 2019. For each year to date period presented, international sales were 40% of total sales. |
| • | Our effective tax rate in the third quarter was 14.4% compared to 21.4% in the prior year third quarter; the fiscal 2020 year to date effective tax rate was 15.6% compared to 17.0% for the same period a year ago. |
| • | Net income for the quarter ended February 29, 2020 was $12.2 million, or $0.23 per diluted share, a decrease of 7% compared to $13.1 million, or $0.25 per share in the same period in the prior year. For the year to date, net income was $43.1 million, or $0.82 per share, a decrease of 3% compared to prior year to date net income of $44.4 million, or $0.85 per diluted share. |
| • | Cash provided from operating activities in the first nine months of fiscal 2020 was $60.3 million, compared to $43.0 million in the same period of fiscal 2019. |
| Three Months Ended February 29, 2020 |
Nine Months Ended February 29, 2020 |
|||||||||||||||
| Revenue |
Revenue |
Revenue |
Revenue |
|||||||||||||
| % Increase/(Decrease) USD |
% Increase/(Decrease) Local Currency |
% Increase USD |
% Increase Local Currency |
|||||||||||||
| UK Companies |
5 |
% | 4 |
% | 3 |
% | 5 |
% | ||||||||
| Brazilian Companies |
(16 |
)% | (6 |
)% | (5 |
)% | 1 |
% | ||||||||
| Neogen Latinoamerica |
15 |
% | 11 |
% | 8 |
% | 7 |
% | ||||||||
| Neogen China |
37 |
% | 41 |
% | 20 |
% | 24 |
% | ||||||||
| Neogen India |
18 |
% | 19 |
% | 11 |
% | 11 |
% | ||||||||
| Neogen Canada |
75 |
% | 73 |
% | 135 |
% | 135 |
% | ||||||||
| Neogen Australasia |
7 |
% | 12 |
% | 15 |
% | 22 |
% | ||||||||
| Three Months Ended February 29/28, |
||||||||||||||||
| 2020 |
2019 |
Increase/ (Decrease) |
% |
|||||||||||||
| (in thousands) |
||||||||||||||||
| Food Safety |
||||||||||||||||
| Natural Toxins, Allergens & Drug Residues |
$ | 17,154 |
$ | 18,612 |
$ | (1,458 |
) | (8 |
)% | |||||||
| Bacterial & General Sanitation |
9,413 |
9,519 |
(106 |
) | (1 |
)% | ||||||||||
| Culture Media & Other |
11,222 |
11,893 |
(671 |
) | (6 |
)% | ||||||||||
| Rodenticides, Insecticides & Disinfectants |
7,964 |
5,953 |
2,011 |
34 |
% | |||||||||||
| Genomics Services |
4,745 |
5,136 |
(391 |
) | (8 |
)% | ||||||||||
| $ | 50,498 |
$ | 51,113 |
$ | (615 |
) | (1 |
)% | ||||||||
| Animal Safety |
||||||||||||||||
| Life Sciences |
$ | 1,376 |
$ | 1,823 |
$ | (447 |
) | (25 |
)% | |||||||
| Veterinary Instruments & Disposables |
10,799 |
10,682 |
117 |
1 |
% | |||||||||||
| Animal Care & Other |
6,667 |
6,554 |
113 |
2 |
% | |||||||||||
| Rodenticides, Insecticides & Disinfectants |
14,558 |
13,525 |
1,033 |
8 |
% | |||||||||||
| Genomics Services |
15,971 |
14,003 |
1,968 |
14 |
% | |||||||||||
| $ | 49,371 |
$ | 46,587 |
$ | 2,784 |
6 |
% | |||||||||
| Total Revenues |
$ | 99,869 |
$ | 97,700 |
$ | 2,169 |
2 |
% | ||||||||
| Nine Months Ended February 29/28, |
||||||||||||||||
| 2020 |
2019 |
Increase/ (Decrease) |
% |
|||||||||||||
| (in thousands) |
||||||||||||||||
| Food Safety |
||||||||||||||||
| Natural Toxins, Allergens & Drug Residues |
$ | 57,950 |
$ | 58,021 |
$ | (71 |
) | 0 |
% | |||||||
| Bacterial & General Sanitation |
31,345 |
30,807 |
538 |
2 |
% | |||||||||||
| Culture Media & Other |
35,259 |
36,302 |
(1,043 |
) | (3 |
)% | ||||||||||
| Rodenticides, Insecticides & Disinfectants |
20,859 |
18,521 |
2,338 |
13 |
% | |||||||||||
| Genomics Services |
12,961 |
13,395 |
(434 |
) | (3 |
)% | ||||||||||
| $ | 158,374 |
$ | 157,046 |
$ | 1,328 |
1 |
% | |||||||||
| Animal Safety |
||||||||||||||||
| Life Sciences |
$ | 4,901 |
$ | 5,794 |
$ | (893 |
) | (15 |
)% | |||||||
| Veterinary Instruments & Disposables |
32,621 |
32,769 |
(148 |
) | 0 |
% | ||||||||||
| Animal Care & Other |
20,859 |
21,900 |
(1,041 |
) | (5 |
)% | ||||||||||
| Rodenticides, Insecticides & Disinfectants |
47,462 |
49,460 |
(1,998 |
) | (4 |
)% | ||||||||||
| Genomics Services |
44,879 |
37,455 |
7,424 |
20 |
% | |||||||||||
| $ | 150,722 |
$ | 147,378 |
$ | 3,344 |
2 |
% | |||||||||
| Total Revenues |
$ | 309,096 |
$ | 304,424 |
$ | 4,672 |
2 |
% | ||||||||
| Three Months Ended |
Nine Months Ended |
|||||||||||||||
| February 29/28 |
February 29/28 |
|||||||||||||||
| (dollars in thousands) |
2020 |
2019 |
2020 |
2019 |
||||||||||||
| Interest income (net of expense) |
$ | 1,600 |
$ | 1,335 |
$ | 4,381 |
$ | 3,290 |
||||||||
| Foreign currency transactions |
(420 |
) | 104 |
(889 |
) | (354 |
) | |||||||||
| Royalty income |
— |
— |
1 |
60 |
||||||||||||
| Deoxi contingent consideration |
— |
— |
— |
(9 |
) | |||||||||||
| Quat-Chem contingent consideration |
— |
— |
— |
422 |
||||||||||||
| Other |
28 |
545 |
56 |
688 |
||||||||||||
| Total Other Income |
$ | 1,208 |
$ | 1,984 |
$ | 3,549 |
$ | 4,097 |
||||||||
Item 3. |
Quantitative and Qualitative Disclosures About Market Risk |
Item 4. |
Controls and Procedures |
Evaluation |
of Disclosure Controls and Procedures |
Item 1. |
Legal Proceedings |
Item 1A. |
Risk Factors |
Item 6. |
Exhibits |
| 3 |
||||
| 10 |
||||
| 31.1 |
||||
| 31.2 |
||||
| 32 |
||||
| 101.INS |
Inline XBRL Instance Document | |||
| 101.SCH |
Inline XBRL Taxonomy Extension Schema Document | |||
| 101.CAL |
Inline XBRL Taxonomy Extension Calculation Linkbase Document | |||
| 101.DEF |
Inline XBRL Taxonomy Extension Definition Document | |||
| 101.LAB |
Inline XBRL Taxonomy Extension Label Linkbase Document | |||
| 101.PRE |
Inline XBRL Taxonomy Extension Presentation Linkbase Document | |||
| EX-104 |
Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101) |
| NEOGEN CORPORATION | ||||||
| (Registrant) | ||||||
| Dated: April 3, 2020 |
||||||
| /s/ John E. Adent | ||||||
| John E. Adent | ||||||
| President & Chief Executive Officer | ||||||
| (Principal Executive Officer) | ||||||
| Dated: April 3, 2020 |
||||||
| /s/ Steven J. Quinlan | ||||||
| Steven J. Quinlan | ||||||
| Vice President & Chief Financial Officer | ||||||
| (Principal Financial Officer and Principal Accounting Officer) |
13a. – CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER
NEOGEN CORPORATION AND SUBSIDIARIES
CEO CERTIFICATION
I, John E. Adent, certify that:
| 1. | I have reviewed this Quarterly Report on Form 10-Q for the period ended February 29, 2020 of Neogen Corporation; |
| 2. | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
| 3. | Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; |
| 4. | The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: |
| a) | designed such disclosure controls and procedures or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; and |
| b) | designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; and |
| c) | evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and |
| d) | disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting. |
| 5. | The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting to the registrant’s auditors and the audit committee of registrant’s board of directors: |
| a) | all significant deficiencies and material weaknesses in the design or operation of internal controls over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and |
| b) | any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting. |
Dated: April 3, 2020
| /s/ John E. Adent |
| John E. Adent |
| President & Chief Executive Officer |
| (Principal Executive Officer) |
13a. – CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER
NEOGEN CORPORATION AND SUBSIDIARIES
CFO CERTIFICATION
I, Steven J. Quinlan, certify that:
| 1. | I have reviewed this Quarterly Report on Form 10-Q for the period ended February 29, 2020 of Neogen Corporation; |
| 2. | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
| 3. | Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; |
| 4. | The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: |
| a) | designed such disclosure controls and procedures or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; and |
| b) | designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; and |
| c) | evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and |
| d) | disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting. |
| 5. | The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting to the registrant’s auditors and the audit committee of registrant’s board of directors: |
| a) | all significant deficiencies and material weaknesses in the design or operation of internal controls over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and |
| b) | any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting. |
Dated: April 3, 2020
| /s/ Steven J. Quinlan |
| Steven J. Quinlan |
| Vice President & Chief Financial Officer |
| (Principal Financial Officer and Principal Accounting Officer) |
18 U.S.C. SECTION 1350 CERTIFICATION
NEOGEN CORPORATION
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with this Quarterly Report on Form 10-Q of Neogen Corporation (the “Company”) for the period ended February 29, 2020 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, John E. Adent, as Chief Executive Officer of the Company and I, Steven J. Quinlan, as Chief Financial Officer, hereby certify pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:
| (1) | This Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
| (2) | Information contained in this Report fairly presents, in all material respects, the financial condition and result of operations of the Company. |
Dated: April 3, 2020
| /s/ John E. Adent |
| John E. Adent |
| President & Chief Executive Officer |
| (Principal Executive Officer) |
| /s/ Steven J. Quinlan |
| Steven J. Quinlan |
| Vice President & Chief Financial Officer |
| (Principal Financial Officer and Principal Accounting Officer) |
A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.